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Abstract
Background: Modulation of pre-mRNA splicing by antisense molecules is a promising mechanism of action for gene 
therapeutic drugs. In this study, we have examined the potential of peptide nucleic acid (PNA) 9-aminoacridine 
conjugates to modulate the pre-mRNA splicing of the mdm2 human cancer gene in JAR cells.
Methods: We screened 10 different 15 mer PNAs targeting intron2 at both the 5' - and the 3'-splice site for their effects 
on the splicing of mdm2 using RT-PCR analysis. We also tested a PNA (2512) targeting the 3'-splice site of intron3 with a 
complementarity of 4 bases to intron3 and 11 bases to exon4 for its splicing modulation effect. This PNA2512 was 
further tested for the effects on the mdm2 protein level as well as for inhibition of cell growth in combination with the 
DNA damaging agent camptothecin (CPT).
Results: We show that several of these PNAs effectively inhibit the splicing thereby producing a larger mRNA still 
containing intron2, while skipping of exon3 was not observed by any of these PNAs. The most effective PNA (PNA2406) 
targeting the 3'-splice site of intron2 had a complementarity of 4 bases to intron2 and 11 bases to exon3. PNA (2512) 
targeting the 3'-splice site of intron3 induced both splicing inhibition (intron3 skipping) and skipping of exon4. 
Furthermore, treatment of JAR cells with this PNA resulted in a reduction in the level of MDM2 protein and a 
concomitant increase in the level of tumor suppressor p53. In addition, a combination of this PNA with CPT inhibited 
cell growth more than CPT alone.
Conclusion: We have identified several PNAs targeting the 5'- or 3'-splice sites in intron2 or the 3'-splice site of intron3 
of mdm2 pre-mRNA which can inhibit splicing. Antisense targeting of splice junctions of mdm2 pre-mRNA may be a 
powerful method to evaluate the cellular function of MDM2 splice variants as well as a promising approach for 
discovery of mdm2 targeted anticancer drugs.
Background
Antisense molecules with significantly modified back-
bones such as peptide nucleic acids (PNA), methoxy-
ethoxy (MOE) and locked nucleic acids (LNA), or
morpholino oligos, rendering them RNase H inactive, are
able to modulate mRNA splicing when targeting intron-
exon junctions in pre-mRNA [1-7]. For instance correc-
t i o n  o f  a b e r r a n t  s p l i c i n g  b y  b l o c k i n g  c ryp t i c  5 ' -  o r  3 ' -
splice sites, induction of exon skipping [8-10] and force
se lection of an alterna tive splice sit e by tar geting anti-
sense molecules to original splice sites [11] have been
demonstrated. Thus antisense targeting of splice junc-
tions have the potential of inducing shifts in the ratio
between biologically functional splice variants or even
induce non-natural splice variants with novel biological
function of the resulting protein. Therefore, splicing tar-
geting technology may open a range of opportunities for
gene targeting in drug discovery and molecular biology
contexts [5,12,13].
The mdm2 oncogene is amplified and/or over
expressed in several cancer types [14]. This oncogene
encodes a protein that negatively controls the functions
of the p53 tumor suppressor protein by blocking the
transactivation domain and by stimulating the degrada-
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tion of p53. Down regulation of MDM2 has been recog-
nized as a potential mechanism for cancer therapy [15,16]
because down-regulation of MDM2 in tumors exhibiting
MDM2 over-expression should induce p53 stability and
thus sensitization to DNA-damaging treatments via p53-
dependent pathways [17-20]. Accordingly, recent studies
have shown down regulation of full-length MDM2 pro-
tein through a traditional RnaseH dependent antisense
approach. In addition, more than 40 different splice vari-
ants of mdm2 mRNA have been detected in tumors and
normal cells [17,21], but the potential functions or onco-
genic properties of the different MDM2 isoforms are far
from fully understood [22-24]. Therefore, targeting of
mdm2 mRNA splicing could be an effective way of con-
trolling and studying overall MDM2 expression and func-
tion.
It has recently been shown that PNA oligomers tar-
geted to exon-intron splice junctions are potent inhibi-
tors/modulators of mRNA splicing [6,25]. By targeting a
3'- splice site, at least two outcomes have been found
although no systematic studies have yet been published.
The spliceosome will either skip the exon and thus pro-
duce a truncated mRNA missing the exon, or skip the
intron excision and thereby produce a larger mRNA still
containing the intron. Therefore, PNA molecules
designed to down-regulate full length mdm2 mRNA or
s h i f t  r e l a t i v e  p o p u l a t i o n s  o f  s p l i c e  v a r i a n t s  b y  s p l i c i n g
m o d u l a t i o n  m a y  b e  a  u s e f u l  a p p r o a c h  f o r  b o t h  f u t u r e
therapy as recently indicated for PNA targeting of CD40
pre-mRNA (7), as well as for investigating the functions
of mdm2 splice variants [17]. However, limited informa-
tion is available concerning the optimum design of anti-
sense PNA oligomers, including target location, for the
desired splicing modulation [6,7,26]. Therefore we
decided to perform a more systematic study of PNA oli-
gomers targeting the 5'- or 3'-splice sites in the human
MDM2 gene.
In this study, we have tested ten PNAs (15-mer) target-
ing intron2 (seven PNAs targeting the 3'-splice site and
three PNAs are targeting to the 5'-splice site) as well as a
PNAs targeting the 3'-splice site of intron3. Depending
on the target site intron and/or exon skipping was
observed, and most interestingly targeting of intron2 also
affected the splicing of intron3. Finally, treatment of JAR
cells with the PNA targeting intron3 resulted in a signifi-
cant reduction in the level of MDM2 protein and a con-
comitant increase in the level of tumor suppressor p53
Methods
Synthesis of PNA
The sequences of the PNAs and nomenclatures are listed
in Table 1. PNA synthesis was carried out as reported in
elsewhere [27]. PNAs were HPLC-purified and character-
ized by mass spectrometry. N-(9-aminoaciridinyl)-6-
aminohexanoic acid (Acr) was covalently linked to the
PNA at the N-terminal of the PNA [20] through an ethyl-
eneglycol type linker (eg1, 8-amino-3,6-dioxaoctanoic
acid) (Acr-PNA). Purified PNAs were lyophilized and
stored at 4°C until use.
Cell culture
JAR cells were provided by Dr. Peter Ebbesen (The Stem
Cell Laboratory, Aalborg University, Denmark). The cells
were cultured in RPMI-1640 medium (Sigma) supple-
mented with 10% fetal bovine serum (FBS), 1.5% gluta-
max (Gibco) and streptomycin/penicillin (100 U/ml
each)) at 37°C in a humidified atmosphere of 95% air and
5% CO2.
PNA transfection
Exponentially growing cells were cultured in 6 well plates
the day before transfection to give 40-60% confluency at
the time of transfection. LipofectAMINE (LFA, Gibco) or
LipofectAMINE2000 (LFA2000, Gibco) was used for the
transfection of the PNAs with Acr modification. LFA was
used unless otherwise stated. The PNA solution (200 μM
in water) was heated for 2 minutes at 90°C then cooled to
room temperature and used as stock solution. In a sepa-
rate tube, LFA or LFA2000 was diluted with OPTI-MEM
(Gibco) at a ratio of 120 μl/ml and 80 μl/ml, respectively.
Then the diluted LFA or LFA2000 solution was mixed
with an equal volume of the PNA solution and incubated
for 5 min, and finally 200 μl Acr-PNA/LFA solution was
mixed with 800 μl of OPTI-MEM or the RPMI medium
(10% FBS, 1% glutamax) respectively for LFA and
LFA2000. This PNA transfection solution was added to
the cells after removing the growth medium using 0.5 ml
or 0.1 ml/well for in 24 well plate or 96 well plate, respec-
tively. After 3-6 h incubation, the cells were supple-
mented with 1 ml of growth medium (RPMI1640
containing 10% FBS and 1.5% glutamax) and incubated
further up to 24 h. The PNA2967 and PNA2968 (PNAs
with oligoarginine) were transfected without cationic lip-
ids and 120 μM chloroquine (CQ) was added to the
OPTI-MEM for the CQ treatment. Nomenclatures and
sequences of PNAs are listed in table 1. The positions of
the PNA target sites are illustrated in Figure 1.
RT-PCR analysis
24 h after transfection, total RNA was extracted from the
cells by using RNeasy Mini kit (Qiagen) and subjected to
RT-PCR. RT-PCR was performed using the OneStep RT-
PCR kit (Qiagen). 4 ng of total RNA was used for each
RT-PCR reaction (20 μl). Primers for RT-PCR detection
of splice sites of mdm2 pre-mRNA and β-actin (as inter-
nal control) are listed in Table 2. The RT-PCR program
was as follows: (55°C, 35 min) × 1 cycle, (95°C, 15 min) ×
1 cycle, (94°C, 1 min; 55°C, 1 min; 72°C, 1 min) × 26-30Shiraishi et al. BMC Cancer 2010, 10:342
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cycles. RT-PCR products were analyzed on 2% agarose
gels with 1 × TBE buffer and visualized by ethidium bro-
mide staining. Gel images were captured by ImageMaster
(Pharmacia Biotech) and analyzed by UN-SCAN-IT soft-
ware (Silk Scientific Corporation). It is important to note
that the RT-PCR experiments cannot be used for absolute
quantification from one set of experiments to the next
due to variations in RNA extraction, RT-PCR amplifica-
tion and gel analysis. Thus the results are reported rela-
tive to the internal control (β-actin).
Western blot analysis
Cells were transfected with PNA as described above and
subjected to protein sample preparation: The cells were
lysed in boiling lysis buffer (1% SDS, 10 mM Tris-HCl, pH
7.2, 1X protease inhibitor cocktail tablet (Roche, Ger-
many)), and 40 μg of the protein was fractionated by SDS-
polyacrylamide gel electrophoresis (SDS-10% PAGE) and
transferred to a PVDF-membrane (ADVANTEC MFS).
Blocking, detection and re-probing were performed with
the ECL-Plus system (Amersham) following the manu-
facture's instruction. Briefly, the PVDF-membrane was
blocked with 5% skim milk (in 20 mM Tris-HCl, pH 7.2,
150 mM NaCl, 0.1% Tween 20) over night at 4°C and
incubated with a primary antibody (anti-MDM2, SMP14
(Sigma); anti-p53, ab6 (Santa Cruz); anti-β-actin, AC-15,
(Sigma)) overnight at 4°C. The membrane was washed
with washing buffer (20 mM Tris-HCl, pH 7.2, 150 mM
NaCl, 0.01% Tween 20) three times for a minimum of 15
min each at room temperature, and then incubated with
1:20000 diluted anti-mouse IgG-horse radish peroxidase
conjugated secondary antibody (DAKO, P0161) for 1 h at
room temperature. After washing as described above, the
protein of interest was detected with ECL-Plus (Amer-
sham).
Cytotoxicity test
JAR cells, plated in a 96 well plate the day before transfec-
tion, were subjected to PNA transfection in combination
with camptothecin (CPT) treatment. CPT was added to
the PNA transfection solution at the desired concentra-
tion and incubated for 48 h. Subsequently, cell viability
was determined by the MTS-assay using the CellTiter 96
Aqueous Non-Radioactive Cell Proliferation Assay (Pro-
Table 1: Nomenclatures and sequences of PNAs
Target (a) PNA No. Sequence (a)
5'-Int2 PNA2545 H-Acr-eg1- TCG GTG CTT ACC TGG-NH2
PNA2547 H-Acr-eg1-TGC TTA CCT GGA TCA-NH2
PNA2549 H-Acr-eg1-TTA CCT GGA TCA GCA-NH2
3'-Int2 PNA2551 H-Acr-eg1-TGT TGG TAT TGC ACA-NH2
PNA2553 H-Acr-eg1-TGG TAT TGC ACA TTT-NH2
PNA2555 H-Acr-eg1-TAT TGC ACA TTT GCC-NH2
PNA2406 H-Acr-eg1-TGC ACA TTT GCC TAC-NH2
PNA2557 H-Acr-eg1-ACA TTT GCC TAC AAG-NH2
PNA2559 H-Acr-eg1-TTT GCC TAC AAG GAA-NH2
PNA2561 H-Acr-eg1-GCC TAC AAG GAA AAA-NH2
3'-Int3 PNA2512 H-Acr-eg1-TTT GGT CTA ACC TAT -NH2
PNA2967 H-(D-Arg)8-TTT GGT CTA ACC TAT-NH2
PNA2968 H-(D-Arg)8-Lys(Deca)-TTT GGT CTA ACC 
TAT-NH2
PNA2406 mismatch PNA2681 H-Acr-eg1-TGC AGA TTT CCC TAC-NH2
PNA2512 mismatch PNA2733 H-Acr-eg1-TTT AGT CTA GCC TAT -NH2
(a) Three PNAs are targeted to the 5'- splice site of intron2 of mdm2 pre-mRNA (5'-Int2). Seven PNAs are targeted to the 3'-splice site of intron2 
(3'-Int2). PNA 2512 is targeted to the 3'- slice site of intron3 (3'-Int3). PNA2681 and PNA2733 are mismatch control PNAs for PNA2406 and 
PNA2512, respectively. Mismatches are indicated in bold. (b) The sequences of the PNAs (15-mer) are written from N-terminal to C-terminal-
end. Acr and eg1 indicate 9-aminoacridinyl ligand and ethyleneglycol linker (8-amino-3,6-dioxaoctanoic acid), respectively.Shiraishi et al. BMC Cancer 2010, 10:342
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mega) according to the manufacturer's instructions. The
absorbance is presented as relative cellular viability
(absorbance from non-PNA treated cells was set as
100%).
Results and Discussion
Ten PNAs targeting intron2 at the 5' or 3' splice sites were
tested for their ability to inhibit splicing of mdm2 pre-
mRNA. As the first in frame AUG translation start codon
is located in exon3, we focused on splice interference that
might result in exon3 skipping, thereby prohibiting any
translation initiation from the mRNA. In order to facili-
tate cellular uptake, we used 9-aminoacridine conjugated
PNAs in combination with cationic lipid transfection
reagent as previously described [20].
Three PNAs (PNA 2545, 2547 and 2549), targeting the
5'-splice site of intron2 (Figure 1(a)), were tested at 2 μM.
S p l i c i n g  i n h i b i t o r y  e f f e c t s  w e r e  a n a l y z e d  b y  R T - P C R
amplifying a region covering the 3'-splice site of intron2
using primer set C (primer sets are listed in Table 2) to
detect mRNA still including intron2. The 3'-splice site
was used instead of the 5'-splice site to avoid RT-PCR
inhibition by PNA targeting the 5'-splice site. PNA2549
(complementary to 11 bases of exon2 and 4 bases of
intron2) showed the highest splicing inhibition among
the three nested PNAs, and PNA 2547 did not show any
significant splicing inhibition (Figure 2). Exon skipping
was not detected for any of these PNAs (at 2 μM concen-
tration).
The effects of seven PNAs targeting the 3'-splice site of
intron2 (Figure 1(b)), were compared by RT-PCR amplifi-
cation of a region including the 5'-splice site of intron2
(Figure 3). The PNAs were tested at 2 μM concentration
and of the seven PNAs, one PNA (2406) was clearly more
active, four PNAs (2551, 2553, 2557 and 2559) did inhibit
splicing to a significant degree, while two PNAs (2555
and 2561) showed no activity (same as no PNA control).
A direct comparison between PNAs 2406, 2549, 2551 and
2553 clearly showed the highest activity for PNA 2406
(Figure 4), and we therefore decided to focus further
studies on this PNA. The limited data also indicate that
the most active PNAs for a given splice junction (PNA
2549 and 2406) should be positioned over the junction
with a bias (75%) to the exon side.
Inhibition of intron2-exon3 cleavage by PNA2406
exhibited a clear dose response (Figure 5A), and a control
PNA (2681) having two mismatches in the sequence (by
nucleobase interchange) in contrast to PNA 2406 showed
no activity at 2 μM (Figure 5B). Next we asked whether
blocking of the intron2-exon3 junction by PNA 2406 had
any other effects on splicing such as skipping of exon3 or
inhibition of the splicing of adjacent introns. These
experiments were performed by RT-PCR using the prim-
ers indicated in Figure 6A. The results (Figure 6C) very
clearly show no indication of significant skipping of
exon3 (112 bp). Because this sequence does not include
the PNA target, the RT-PCR reaction is not inhibited by
the PNA. In contrast the splicing inhibited product (318
bp) does contain the PNA target, and this is decreased in
the PNA treated sample. Also the effect of the PNA is
note solely localized to the targeted intron but does affect
splicing of adjacent introns. For example the amount of
unspliced intron 3 is increased 2-4-fold (Fig 6(B) (b) and
6(c)), while no significant change of intron 4 splicing was
detected (Figure 6 (B), (d) and 6(e)).
To validate the target design of PNA for efficient splic-
ing inhibition, we designed another PNA (PNA2512) tar-
geting the 3'-splice site in intron3 with a complementary
of 4 bases in intron3 and 11 bases in exon4 (Figure 1C).
The effect of PNA2512 on splicing at intron2, 3 and 4 was
analyzed by detecting the regions including the 5' or 3'
splice sites of intron2, 3, and 4 (Figure 7A, region (a) - (e)).
Only inhibition of splicing out of intron3 was observed in
this case. Furthermore, in contrast to PNA2406,
PNA2512 induced skipping of exon4 in addition to intron
skipping (Figure 7B-(c), Figure 7C). PNA2512 showed a
dose-dependent increase of the skipped form and
decrease of the normal form (ca 1/3 conversion at 4 μM),
while there was no such effect with the mismatch PNA.
This PNA oligomer was further studied by using a differ-
ent cellular delivery method not requiring cationic lipid
assistance, but based on cell penetrating peptides (CPP).
In this case the PNA was conjugated to octaarginine
(PNA2967) or to decanoyl-octaarginine, having decanoic
acid (as a lipidic domain) attached to the ε-amine of Lys
side chain (Cat-Lip-PNA [28], PNA2968). These PNAs
were transfected to the cells both in the absence or the
Figure 1 The MDM2 gene and PNA target positions. (A) The re-
gions of mdm2 pre-mRNA used as targets for PNAs are indicated with 
thick bars under the exons ((a), (b) and (c)). Numbered boxes: exons; 
lines: introns. (B) The exact sequence position of PNAs targeted to the 
5'-splice site of intron2 (a), 3'-splice site of intron2 (b) and 3'-splice site 
of intron3 (c) are shown. Intron sequences are in lower case.
1 2 3 4 5 12
Exon2   Intron2
TGCTGATCCAGgtaagcaccga
PNA2545
PNA2547
PNA2549
(a)
Intron 2   Exon3
GCAAATGTGCAATACCAACA tttttccttgtag
PNA2551
PNA2553
PNA2555
PNA2406
PNA2557
PNA2559
PNA2561
(b)
atag
PNA2512
GTTAGACCAAA
Intron3   Exon4
(c)
(a) (b) (c)
(A)
(B)Shiraishi et al. BMC Cancer 2010, 10:342
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presence of the endosomolytic reagent chloroquine (CQ)
since CQ is known to improve the cellular activity of CPP
conjugates (Figure 8) [29]. The PNAs showed exon skip-
ping activity in a dose dependent manner and the effect
was significantly improvement upon CQ addition. As
expected (28) the Cat-Lip PNA2968 exhibited the higher
activity reaching more than 50% conversion at 6 μM in
the presence of CQ, Although the activity of this PNA in
the absence of CQ - somewhat surprisingly - is lower than
that exhibited by lipofectamine mediated delivery of
PNA2512, it is still higher than that observed for the anal-
ogous arginine PNA2967. Furthermore, CPP-PNA medi-
ate splicing modulation is of considerable interest, since
CPP delivery in contrast to lipofectamine mediated deliv-
ery holds some promise for in vivo and eventually thera-
peutic use [30,31].
Because PNA 2512 produced a combination of intron
and exon skipped mRNA forms both of which would pro-
hibit correct protein translation, we decided to analyze
the effect of treatment with this PNA on the protein
expression level of mdm2 as well as of p53, which is
directly regulated by mdm2. After PNA treatment, cellu-
lar proteins were subjected to western blot analysis. As
shown in Figure 9, PNA2512 induced a significant, dose
dependent decrease of MDM2 (90 kDa) protein levels at 2
μM and 4 μM (while mismatch PNA (PNA2733, with two
base pairs internal exchange) clearly induced less
decrease of the MDM2 than full matched PNA at the
same concentrations). No evidence for accumulation of
any truncated MDM2 protein from the truncated mRNA
missing exon4 (mw 52374) or from the splicing-inhibited
mRNA containing intron3 which contains a termination
Table 2: Nomenclatures of primer sets and sequences of RT-PCR primers.
Primer set(a), Primer name sequence (5'T3') Product size (bp) Remarks
A Exo2S CGATTGGAGGGTAGACCTGT 161 intron2 5'-splice site
Int2AS CACGATGAAAACTGGAAATCA
B Int2Sa TGCTTGTAGCTTTAGTTTTA 90 intron2
Int2AS CACGATGAAAACTGGAAATCA
C Int2Sb GATTTCCAGTTTTCATCGTGT 120 intron2 3'-splice site
Exo3AS GGTCTCTTGTTCCGAAGCTG
D Exo3S CAGCTTCGGAACAAGAGACC 169 intron3 5'-splice site
Int3AS GCAGTTACGCCAGAGGTAGC
E Int3S TCTTTGCTCTTTTGGATTGGA 251 intron3 3'-splice site
Exo4AS TTTTTGTGCACCAACAGACTTT
F Exo4S AAGCCATTGCTTTTGAAGTTATT 151 intron4 5'-splice site
Int4AS GCCAATTTCTCCACATGGTC
G Int4S TGGTTCCTGGTTGTTTACCC 215 intron5 3'-splice site
Exo5AS CACGCCAAACAAATCTCCTA
H ActF1 CCCTGGAGAAGAGCTACGAG 223 β-actin (771-993)
ActR1 ATGCCAGGGTACATGGTGGT
I ActF2 CTTCCTGGGCATGGAGTC 166 β-actin (862-1027)
ActR2 CAGGGCAGTGATCTCCTTCT
(a)A-H indicates the target sequences for RT-PCR within the mdm2 pre-mRNA. For primer set H and I, location of the amplification products 
within the β-actin (Accsession#, BC001301) are indicated.Shiraishi et al. BMC Cancer 2010, 10:342
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codon (calc mw 3823) was seen at the tested PNA con-
centrations. Furthermore, PNA2512 induced a several
fold increase of p53 protein level which was not observed
with the control PNA2733. This effect is ascribed to the
reduction in MDM2 protein level via the "negative feed-
back regulation" mechanism [16]. Whether simply inhib-
iting MDM2 synthesis is most effectively achieved via
targeting of splicing as described in the present report or
through direct translational inhibition as previously
found [20] remains to be established by further optimiza-
tion and direct comparison although the data so far indi-
cate comparable potency.
Figure 2 Effect of PNAs on the splicing of intron2 in mdm2 pre-
mRNA. Splicing inhibition of three PNAs (PNA2545, 2547 and 2549) tar-
geted to the 5'-splice site of intron2 in mdm2 pre-mRNA. JAR cells were 
transfected with PNA (2 μM) for 24 h and subjected to RT-PCR analysis 
by using extracted total RNA. RT-PCR was performed with primer sets 
C and H (see Table 2), for 3'-splice site of the intron2 (120 bp) and β-
actin (223 bp) (as internal control), respectively. Results of RT-PCR with 
27 cycles are shown. The numbers under the figure indicate the rela-
tive amount (normalized to β-actin) of the target mdm2 splicing vari-
ant.
β β β β-actin 
(223 bp)
(120 bp)
no PNA
PNA2545
PNA2547
PNA2549
3
0.12   0.53   0.21   0.68
Figure 3 Effect of PNAs on the splicing of intron2. Splicing inhibi-
tion of intron2 in mdm2 pre-mRNA by seven PNAs (PNA2551, 2553, 
2555, 2406, 2557, 2559 and 2561) targeted to the 3'-splice site of 
intron2. JAR cells were transfected with PNA (2 μM) for 24 h and sub-
jected to RT-PCR analysis by using extracted total RNA. RT-PCR was per-
formed with primer sets A and H (see Table 2), for the 5'-splice site of 
the intron2 (161 bp) and β-actin (223 bp) (as internal control), respec-
tively. RT-PCR results with 27 PCR cycles for three PNAs (PNA2551, 2553 
and 2555) (A) and four PNAs (PNA2406, 2557, 2559 and 2561) (B) are 
shown. The numbers under the figure indicate the relative amount 
(normalized to β-actin) of the target mdm2 splicing variant.
(A)
no PNA
PNA2551
PNA2553
PNA2555
β β β β-actin 
(223 bp)
(161 bp)
2
(B)
no PNA
PNA2406
PNA2557
PNA2559
PNA2561
β β β β-actin 
(223 bp)
(161 bp)
2
0 .1 3    0 . 4 1    0 . 4 4    0 . 1 2
0.05   0.96   0.43   0.40   0.05
Figure 4 Effect of PNAs on the splicing of intron2. Comparison of 
PNAs 2549, 2406, 2551 and 2553 in terms of splicing inhibition of 
intron2 in mdm2 pre-mRNA. JAR cells were transfected with PNAs (2 
μM) for 24 h and subjected to RT-PCR analysis using extracted total 
RNA. RT-PCR was performed with primer sets B and H (see Table 2), for 
intron2 in mdm2 pre-mRNA (90 bp) and β-actin (223 bp) (as internal 
control), respectively. RT-PCR results with 27 PCR cycles are shown. The 
numbers under the figure indicate the relative amount (normalized to 
β-actin) of the target mdm2 splicing variant.
no PNA
PNA2549
PNA2406
PNA2551
PNA2553
β β β β-actin 
(223 bp)
(90 bp) 0.05   0.26   0.49   0.21   0.09
Figure 5 Effect of PNA2406 on the splicing of intron2. JAR cells 
were transfected with PNAs at the indicated concentrations for 24 h 
and subjected to RT-PCR analysis using extracted total RNA. RT-PCR 
was performed with primer sets A and H (see Table 2) for 5'-splice site 
of intron2 in mdm2 pre-mRNA (161 bp) and β-actin (223 bp) (as inter-
nal control), respectively. The numbers under the figure indicate the 
relative amount (normalized to β-actin) of the target mdm2 splicing 
variant. A, Dose dependent splicing inhibition of intron2 by PNA2406 
(1, 2, 4 and 8 μM). 26 PCR cycles was used. B, comparison of PNA2406 
with its mismatch PNA (PNA2681, mismatch) holding two mismatches 
(at 2 μM). 27 PCR cycles was used.
(A)
β β β β-actin 
(223 bp)
(161 bp)
PNA2406 (μ μ μ μM)
0  1  2  4  8
2
(B)
No PNA
PNA2406
mismatch
β β β β-actin 
(223 bp)
(161 bp)
2
0.05   0.13   0.29   0.66   0.80
0.05   0.66   0.06Shiraishi et al. BMC Cancer 2010, 10:342
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Finally, we tested the effect of PNA2512 on cell prolifer-
ation in combination with the topoisomerase I inhibitor
anticancer agent camptothecin (CPT). It could be antici-
pated that DNA-damaging agents that activate the p53
response could act synergistically with antisense agents
that activates p53 by reducing MDM2 levels, as has previ-
ously been indicated employing phosphorothioates [19]
and PNA [20]. Thus the effect of PNA2512 on cell prolif-
eration was evaluated in combination with the DNA-
damaging anticancer agent CPT (Figure 10). Cells treated
with CPT in combination with PNA2512 at 6 μM showed
significantly lower cell viability as compared to CPT
treatment alone or to CPT-treatment in combination
with a mismatch PNA. We also tested lower concentra-
Figure 6 Effect of PNA2406 on the splicing of introns 2, 3 and 4. JAR cells were transfected with PNA2406 at 2 μM for 24 h and subjected to RT-
PCR analysis using the extracted total RNAs. N: no PNA treatment. P: treated with PNA2406 (2 μM). (A) Location of the PNA2406 and splice sites ana-
lyzed ((a), (b), (c), (d) and (e)) are indicated. (B) The structures or names of RT-PCR products are shown on the right of each picture. Primer sets for the 
detection of each splice sites (in Figure 6A) by RT-PCR (product length) are as follows: (a), A (161 bp) and H (β-actin, 223 bp); (b), D (169 bp) and H (β-
actin, 223 bp); (c), E (251 bp) and I (β-actin, 166 bp); (d), F (151 bp) and H (β-actin, 223 bp); (e), G (215 bp) and I (β-actin, 166 bp). The numbers under 
the figure indicate the relative amount (normalized to β-actin) of the target mdm2 splicing variants. (C). Primers, Exo2S and Exo4AS in Table 2, were 
used for RT-PCR for the detection of exon3-skipped form. Locations of the splice inhibited form (inhibited (318 bp)), normal splice form (normal (197 
bp)) and exon3-skipped form (skipped (112 bp)) although the last one (skipped form) was not visible.
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tions of PNA2512 (2 and 4 μM) in combination with CPT
but found no significant effect (data not shown). The
results do not allow us to conclude if the effect is truly
synergistic, but they do indicate that it is more than addi-
tive. However, further experiments are required for more
detailed characterization of cell death induction by PNA
in combination with CPT.
Conclusions
In summary, we have identified several PNAs targeting
the 5' or 3' splice sites in intron2 of mdm2 pre-mRNA
which can inhibit splicing. One of the most efficient
PNAs (PNA2406) is targeting the 3' splice site and is com-
plementary to 4 bases in intron2 and 11 bases in exon3.
Interestingly, PNA2512, which is targeting the 3' splice
Figure 7 Effect of PNA2512 on the splicing of introns 2, 3 and 4. JAR cells were transfected with PNA2512 or mismatch PNA (PNA2733) for 24 h 
and subjected to RT-PCR analysis using extracted total RNA. (A) Location of PNA2512 and detected splice sites ((a), (b), (c), (d) and (e)) are indicated. 
(B) Cells were transfected with PNA2512 (2 μM) and subjected to RT-PCR analysis. N: no PNA treatment. P: treated with PNA2512 (2 μM). The structures 
or names of RT-PCR products are shown on the right of each picture. Primer sets (see table 2) for the detection of each splice site by RT-PCR (product 
length) are as follows: (a), A (161 bp) and H (β-actin, 223 bp); (b), C (120 bp) and H (β-actin, 223 bp); (c), D (169 bp) and H (β-actin, 223 bp); (d), F (151 
bp) and H (β-actin, 223 bp); (e), G (215 bp) and I (β-actin, 166 bp). The numbers under the figure indicate the relative amount (normalized to β-actin) 
of the target mdm2 splicing variants. (C) Effect of PNA2512 on the skipping of exon4. Cells were treated with PNA2512 or its mismatch PNA (PNA2733) 
at the indicated concentrations and subjected to RT-PCR analysis. For the RT-PCR, Exo3S and Exo5AS (primers in Table 2) were used. Locations of the 
normally spliced form (Normal (207 bp)) and exon4-skipped form (skipped (131 bp)) are indicated on the right. Numbers under each lane indicate the 
amount of the skipped form relative to the sum of skipped and normal form.
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site of intron3 and is complementary to 4 bases in intron3
and 11 bases in exon4, showed both splicing inhibition as
well as exon skipping. Furthermore, PNA2406 inhibited
splicing of both intron2 as well as the downstream intron
(intron3), whereas PNA2512 only inhibited the splicing
of intron3 (and not downstream intron4). These results
reflect the complexity of the splicing mechanism and thus the splicing modulation by antisense PNAs (and presum-
ably other antisense agents as well). Further studies are
required to obtain more generally applicable guidelines
for designing antisense PNAs for a desired splicing mod-
ulation. Treatment of JAR cells in culture with the most
potent PNA (2512) for pre-mRNA splicing modulation
also affected protein expression, causing a reduction of
the level of MDM2 protein and (consequently) an
increase in the level of p53. Finally, this PNA increased
the cytotoxicity of the anticancer camptothecin presum-
ably caused by the PNA mediated up-regulation of p53.
In conclusion these results add to the accumulating evi-
dence that antisense mediated mRNA splice modulation
have interesting prospects both within drug discovery but
also as a molecular biology tool. Once more potent in
vivo  PNA delivery methods are available, the present
results provide the basis for further drug discovery stud-
ies.
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Figure 8 Effect of CPP-PNA (PNA2967) and Cat-Lip-PNA 
(PNA2968) on the skipping of exon4. JAR cells were incubated with 
PNA for 4 h in the serum free OPTI-MEM medium (without cationic lip-
ids) in the absence or the presence of 120 μM chloroquine (CQ) and in-
cubated further for 24 h after supplemented a growth medium to have 
10% FBS concentration. Total RNA was extracted and subjected to RT-
PCR using Exo3S and Exo5AS primers (see Table 2). Locations of the 
normally spliced form (Normal, 207 bp) and exon4-skipped form 
(Skipped, 131 bp) are indicated on the right of the pictures. Numbers 
under each lane indicate the amount of the skipped form relative to 
the sum of skipped and normal form.
+ CQ
CPP-PNA
(M)
Cat-Lip-PNA
(M)
no CQ
0   0.6   2   6   0.6   2   6
(%)  0.9   6.3   7.6   12    10   13   25
(%)  0.9   33   40   46   30   47   58
normal 
skipped 
normal 
skipped 
Figure 9 Effect of PNA2512 on the protein level of MDM2 and 
p53. JAR cells were transfected with PNA 2512 or its mismatch PNA 
(PNA2733) and subjected to western blot analysis. Equal amount of 
protein were separated on SDS-PAGE and transferred to PVDF mem-
brane. The membrane was probed with monoclonal antibody for 
MDM2 and reacting proteins were detected using the ECL-Plus system 
(Amersham). The membrane was washed and re-used for detection 
with a monoclonal antibody of p53 or α-tubulin. The numbers under 
the figure indicate the relative amount (normalized to α-tubulin) of the 
target proteins.
- MDM2
- -tubulin
-p 5 3
PNA2512 mismatch
0  1  2  4  2  4 (M)
Figure 10 Influence on cell viability of PNA in combination with 
camptothecin (CPT). JAR cells were transfected with PNA (PNA2512 
or its mismatch (mismatch, PNA2733) at 6 μM) in the presence of 
LFA2000 (8 μl/ml) and CPT at the indicated concentrations for 48 h and 
subjected to the MTS cellular viability assay (Promega). The obtained 
data are normalized to the non-treated sample and shown as relative 
cell viability (%). In the absence of CPT cell viability was 82% and 91% 
in the presence of PNA2512 and mismatch PNA2733, respectively (at 6 
μM). Data are mean ± S.D. of four independent experiments.
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